As of 2025-07-09, the Intrinsic Value of Summit Therapeutics Inc (SMMT) is -1.20 USD. This SMMT valuation is based on the model Peter Lynch Fair Value. With the current market price of 22.99 USD, the upside of Summit Therapeutics Inc is -105.21%.
Based on its market price of 22.99 USD and our intrinsic valuation, Summit Therapeutics Inc (SMMT) is overvalued by 105.21%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -1.20 - -1.20 | -1.20 | -105.21% |
| P/E | (2.46) - (4.46) | (3.21) | -114.0% |
| DDM - Stable | (1.56) - (4.63) | (3.10) | -113.5% |
| DDM - Multi | (0.10) - (0.23) | (0.14) | -100.6% |
| Market Cap (mil) | 17,073.98 |
| Beta | 3.25 |
| Outstanding shares (mil) | 742.67 |
| Enterprise Value (mil) | 16,862.46 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.69% |
| Cost of Debt | 5.00% |
| WACC | 7.68% |